Takeda brings innovative pipeline portfolio to patients for sustained revenue growth
From TakedaDec 10 2020
As part of its Wave 1 Pipeline Market Opportunity Call, Takeda Pharmaceutical Company Limited (“Takeda”) provided an update on its pipeline portfolio, which has the potential to contribute significantly to revenue growth for the company over the next decade. The company also shared its PTS adjusted view for FY2019-FY2030 revenue CAGR (low single-digit), as well as its goal for FY2019-FY2030 revenue CAGR (mid-single-digit), amounting to JPY5 trillion ($47 billion) by FY2030.
The majority of this revenue growth is expected to come from the company’s Wave 1 pipeline, which includes 12 unique New Molecular Entities (NMEs), representing potential best-in-class/first-in-class therapies, and its existing 14 global brands. Of the Wave 1 programs, five have received Breakthrough Therapy designation and three were granted fast track designation by the U.S. Food and Drug Administ